Document is current
Any future updates will be listed below
-
Authors
Tang, Qi https://orcid.org/0000-0002-8913-0519
Fakih, Hassan H. https://orcid.org/0000-0002-7598-0993
Zain UI Abideen, Mohammad
Hildebrand, Samuel R.
Afshari, Khashayar
Gross, Katherine Y.
Sousa, Jacquelyn
Maebius, Allison S.
Bartholdy, Christina
Søgaard, Pia Pernille https://orcid.org/0000-0001-9175-1819
Jackerott, Malene https://orcid.org/0000-0003-4815-2153
Hariharan, Vignesh https://orcid.org/0000-0001-9624-1244
Summers, Ashley https://orcid.org/0000-0002-5425-0457
Fan, Xueli
Okamura, Ken https://orcid.org/0000-0001-7366-3233
Monopoli, Kathryn R. https://orcid.org/0000-0002-8615-4849
Cooper, David A. https://orcid.org/0000-0003-1356-1707
Echeverria, Dimas
Bramato, Brianna
McHugh, Nicholas https://orcid.org/0000-0003-2004-0811
Furgal, Raymond C. https://orcid.org/0000-0002-4757-7339
Dresser, Karen https://orcid.org/0000-0002-8599-4352
Winter, Sarah J.
Biscans, Annabelle https://orcid.org/0000-0001-9953-9265
Chuprin, Jane https://orcid.org/0000-0001-8420-6644
Haddadi, Nazgol-Sadat https://orcid.org/0000-0001-8854-8182
Sherman, Shany
Yıldız-Altay, Ümmügülsüm https://orcid.org/0000-0001-8774-9257
Rashighi, Mehdi
Richmond, Jillian M.
Bouix-Peter, Claire
Blanchard, Carine https://orcid.org/0000-0002-3377-290X
Clauss, Adam https://orcid.org/0000-0002-6381-324X
Alterman, Julia F. https://orcid.org/0000-0002-6195-0857
Khvorova, Anastasia https://orcid.org/0000-0001-6928-8071
Harris, John E. https://orcid.org/0000-0002-7815-6430
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR069114, K99 AR082987)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM131839)
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (S10 OD020012)
- License Information
-
More Information
Article History
Received: 25 May 2023
Accepted: 19 October 2023
First Online: 4 November 2023
Competing interests
: The University of Massachusetts Chan Medical School has patented the JAK1 siRNA sequences (Patent publication numbers: WO2022271666A1; Oligonucleotides for IFN-γ signaling pathway modulation) and the docosanoic acid conjugate (CA3174068A1; Conjugated oligonucleotides for tissue-specific delivery) for the use with therapeutic oligonucleotides, and the outlined technologies in this article has been licensed to Aldena Therapeutics for clinical development. A.K. discloses ownership of stocks in RXi Pharmaceuticals and Advirna; is a founder of Atalanta Therapeutics and Comanche Biopharma; serves on the Scientific Advisory Board of Aldena Therapeutics, Prime Medicine, and Alltrna. J.E.H. holds equity in Rheos Medicines and TeVido BioDevices; is a founder with equity of Villaris Therapeutics, Aldena Therapeutics, NIRA Biosciences, Vimela Therapeutics, and Klirna Therapeutics; has served as a consultant for Pfizer, Sanofi Genzyme, Incyte, Sun Pharmaceuticals, LEO Pharma, Dermavant, Temprian Therapeutics, AbbVie, Janssen, Almirall, Methuselah Health, Pandion, AnaptysBio, Avita, Aclaris Therapeutics, The Expert Institute, BiologicsMD, Boston Pharma, Sonoma Biotherapeutics, Two Biotech, Admirx, Frazier Management, 3rd Rock Ventrures, Gogen Therapeutics, Granular Therapeutics, Platelet Biogenesis, BridgeBio, Merck, Matchpoint Therapeutics, and Klirna; has served as an investigator for Pfizer, Sanofi Genzyme, Incyte, Sun Pharmaceuticals, LEO Pharma, Dermavant, Aclaris Therapeutics, GSK, Celgene, Dermira, and EMD Serono. C.B.P. and C. Blanchard are employed executives of Aldena Therapeutics. The remaining authors declare no competing interests.
